Potassium citrate/potassium hydrogen carbonate

Potassium citrate/potassium hydrogen carbonate
Combination of
Potassium citrateMineral supplement
Potassium hydrogen carbonateMineral supplement
Clinical data
Trade namesSibnayal
Other namesADV7103, potassium citrate/potassium hydrogencarbonate, potassium citrate/potassium bicarbonate
Routes of
administration		By mouth
ATC code
Legal status
Legal status

Potassium citrate/potassium hydrogen carbonate, sold under the brand name Sibnayal, is a fixed-dose combination medication intended for the treatment of distal renal tubular acidosis.[1] It contains potassium citrate and potassium hydrogen carbonate.[1]

Potassium citrate/potassium hydrogen carbonate was approved for medical use in the European Union in April 2021.[1]

  1. ^ a b c d "Sibnayal EPAR". European Medicines Agency (EMA). 9 December 2020. Retrieved 22 May 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  2. ^ "Sibnayal Product information". Union Register of medicinal products. Retrieved 3 March 2023.